Chime Biologics

【Healthcare Insights Luncheon with President of Chime Biologics】 Earlier this month, VMS Group hosted a Healthcare Insights Luncheon, and we were honored to have Dr. Jimmy Wei, President of Chime Biologics sharing his insights with our guests while visiting Hong Kong. Benny Chong, Chairman of VMS Group, emphasized VMS's long-term confidence in the healthcare sector and committed to dedicate our resources to help Chime grow into a global enterprise. During the luncheon, Dr. Jimmy Wei detailed how Chime has gradually transformed from a Chinese CDMO company into a global CDMO leader since its establishment in 2019. Over the past five years, through continuous transformation and integration, Chime has established its differentiated market positioning and development strategy, and built an ecosystem to provide more cost-effective production services to pharmaceutical companies worldwide. 𝐒𝐨, 𝐰𝐡𝐚𝐭 𝐚𝐫𝐞 𝐭𝐡𝐞 𝐟𝐮𝐭𝐮𝐫𝐞 𝐭𝐫𝐞𝐧𝐝𝐬 𝐢𝐧 #𝐡𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐰𝐞 𝐡𝐚𝐯𝐞 𝐥𝐞𝐚𝐫𝐧𝐭 𝐟𝐫𝐨𝐦 𝐃𝐫 𝐖𝐞𝐢? ● The Chinese #biopharmaceutical market is experiencing rapid growth, with an expected CAGR of 30% from 2017 to 2030, significantly outpacing global growth rates. ● The total value of innovative drug out-licensing transactions reached $4.3 billion in 2023, a remarkable 40-fold increase compared to 2019. ● A #globalization strategy is key. Notably, more than half of Chime’s newly signed orders in 2024 come from international markets, demonstrating the effectiveness of its strategy. We would like to thank our guests again for their participation. Keen to learn more? Chime Biologics will be attending the #BIOEurope2024 event in Europe from November 4-6, 2024. VMS Group’s Partner and Head of Healthcare, Andrew Ng, will also be in attendance. Please don’t hesitate to visit and schedule a meeting with Andrew and the Chime team now through the one-on-one partnering system to explore more cooperation opportunities! Schedule now: https://lnkd.in/dSh2WhAN #VMS #HealthcareInvestment #Chime #BIOEurope #MedicalIndustry #CDMO #GlobalHealthcare

【Healthcare Insights Luncheon with President of Chime Biologics】 Earlier this month, VMS Group hosted a Healthcare Insights Luncheon, and we were honored to have Dr. Jimmy Wei, President of Chime Biologics sharing his insights with our guests while visiting Hong Kong. Benny Chong, Chairman of VMS Group, emphasized VMS's long-term confidence in the healthcare sector and committed to dedicate our resources to help Chime grow into a global enterprise. During the luncheon, Dr. Jimmy Wei detailed how Chime has gradually transformed from a Chinese CDMO company into a global CDMO leader since its establishment in 2019. Over the past five years, through continuous transformation and integration, Chime has established its differentiated market positioning and development strategy, and built an ecosystem to provide more cost-effective production services to pharmaceutical companies worldwide. 𝐒𝐨, 𝐰𝐡𝐚𝐭 𝐚𝐫𝐞 𝐭𝐡𝐞 𝐟𝐮𝐭𝐮𝐫𝐞 𝐭𝐫𝐞𝐧𝐝𝐬 𝐢𝐧 #𝐡𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐰𝐞 𝐡𝐚𝐯𝐞 𝐥𝐞𝐚𝐫𝐧𝐭 𝐟𝐫𝐨𝐦 𝐃𝐫 𝐖𝐞𝐢? ● The Chinese #biopharmaceutical market is experiencing rapid growth, with an expected CAGR of 30% from 2017 to 2030, significantly outpacing global growth rates. ● The total value of innovative drug out-licensing transactions reached $4.3 billion in 2023, a remarkable 40-fold increase compared to 2019. ● A #globalization strategy is key. Notably, more than half of Chime’s newly signed orders in 2024 come from international markets, demonstrating the effectiveness of its strategy. We would like to thank our guests again for their participation. Keen to learn more? Chime Biologics will be attending the #BIOEurope2024 event in Europe from November 4-6, 2024. VMS Group’s Partner and Head of Healthcare, Andrew Ng, will also be in attendance. Please don’t hesitate to visit and schedule a meeting with Andrew and the Chime team now through the one-on-one partnering system to explore more cooperation opportunities! Schedule now: https://lnkd.in/dSh2WhAN #VMS #HealthcareInvestment #Chime #BIOEurope #MedicalIndustry #CDMO #GlobalHealthcare

🤝Where Europe Meets China: Biotech Synergy in Action Kick off Day 1 of BIO-Europe by joining us at a side event: the Europe-China Biotech Business Forum 2024! Discover how China's dynamic biotech ecosystem and flexible collaboration models are driving growth and creating new opportunities for European biotech to thrive. This event will highlight how flexible collaboration models and cross-border innovation are accelerating breakthroughs in drug development, from R&D to time-to-market.  Event Details:  • When: Monday, 4 November  • Time: 10 AM - 12 PM  • Where: Room K16, Stockholmsmässan, Stockholm, Sweden 💡Secure your invitation today and join the conversation shaping the future of biotech! Organized by: Chime Biologics, Duoning, Cytiva Supported by: eleva , Topgene Biotechnology, Hengyu Biotech, Hubei Biopark, Biolake  #BIOEurope2024 #ChinaEuropePartnership #Innovation #BiotechBusiness

🎉 We are thrilled to announce strategic collaboration with BioAI in precision oncology using artificial intelligence (AI) to advance targeted immunotherapeutics of bispecific T-cell engagers (TCEs) and antibody-drug conjugates (ADCs). 🎊 We have also entered a strategic alliance with Chime Biologics to accelerate chemistry, manufacturing and control (CMC) process development of the novel designs of ADCs and TCEs. The partnership supports multiple pipelines of about 10 first-in-class and best-in-class immunotherapeutics, including monoclonal, bispecific/biparatopic and TriAx antibodies within the coming 3 years. The collaboration will ensure Arbele continues to have at least 1-2 new molecular entities (NMEs) successfully filing for investigational new drug (IND) application and entering clinical studies in the next 5 years without any technical and supply-chain interruptions. Read more in our press release below. https://lnkd.in/gPGWWR33 #AIoncology #PrecisionMedicine #Immunotherapeutics #Biotech #Diagnostics #CMC #ProcessDevelopment